N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase
摘要:
A series of N1-alkyl pyrimidinediones were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Our efforts identified compound 10b, which represents the lead compound in this series with pharmacokinetics and antiviral potency that may support once-daily dosing. (C) 2010 Elsevier Ltd. All rights reserved.
The invention is related to compounds of Formula (I):
or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
[EN] NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA TRANSCRIPTASE INVERSE DE VIH
申请人:GILEAD SCIENCES INC
公开号:WO2009005693A1
公开(公告)日:2009-01-08
The invention is related to compounds of Formula (I); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase
作者:Michael L. Mitchell、Jong Chan Son、Hongyan Guo、Yun-A Im、Eun Jung Cho、Jianhong Wang、Jaclyn Hayes、Michael Wang、Amber Paul、Eric B. Lansdon、James M. Chen、Doris Graupe、Gerry Rhodes、Gong-Xin He、Romas Geleziunas、Lianhong Xu、Choung U. Kim
DOI:10.1016/j.bmcl.2010.01.085
日期:2010.3
A series of N1-alkyl pyrimidinediones were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Our efforts identified compound 10b, which represents the lead compound in this series with pharmacokinetics and antiviral potency that may support once-daily dosing. (C) 2010 Elsevier Ltd. All rights reserved.